Hantavirus in humans: a review of clinical aspects and management

Simple item page
dc.catalogadoraba
dc.contributor.authorVial Clavo, Pablo Agustín
dc.contributor.authorFerrés, Marcela
dc.contributor.authorVial, Cecilia
dc.contributor.authorKlingstrom, Jonás
dc.contributor.authorAhlm, Clas
dc.contributor.authorLópez, René
dc.contributor.authorLe Corre Pérez, Monique Nicole
dc.contributor.authorMertz J., Gregory
dc.date.accessioned2025-03-31T16:40:49Z
dc.date.available2025-03-31T16:40:49Z
dc.date.issued2023
dc.description.abstractHantavirus infections are part of the broad group of viral haemorrhagic fevers. They are also recognised as a distinct model of an emergent zoonotic infection with a global distribution. Many factors influence their epidemiology and transmission, such as climate, environment, social development, ecology of rodent hosts, and human behaviour in endemic regions. Transmission to humans occurs by exposure to infected rodents in endemic areas; however, Andes hantavirus is unique in that it can be transmitted from person to person. As hantaviruses target endothelial cells, they can affect diverse organ systems; increased vascular permeability is central to pathogenesis. The main clinical syndromes associated with hantaviruses are haemorrhagic fever with renal syndrome (HFRS), which is endemic in Europe and Asia, and hantavirus cardiopulmonary syndrome (HCPS), which is endemic in the Americas. HCPS and HFRS are separate clinical entities, but they share several features and have many overlapping symptoms, signs, and pathogenic alterations. For HCPS in particular, clinical outcomes are highly associated with early clinical suspicion, access to rapid diagnostic testing or algorithms for presumptive diagnosis, and prompt transfer to a facility with critical care units. No specific effective antiviral treatment is available.
dc.description.funderNIH; Folio: U01 AI045452
dc.description.funderFONDECYT; Folio: 1201240
dc.description.funderFONDECYT; Folio: 1211825
dc.description.funderATE; Folio: 220061
dc.description.funderThe Center for Medical Innovation; Folio: 20200141
dc.format.extent12 páginas
dc.fuente.origenORCID
dc.identifier.doi10.1016/S1473-3099(23)00128-7
dc.identifier.eissn1474-4457
dc.identifier.issn1473-3099
dc.identifier.scopusid2-s2.0-85162136592
dc.identifier.urihttps://doi.org/10.1016/S1473-3099(23)00128-7
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/103033
dc.identifier.wosidWOS:001072260600001
dc.information.autorucEscuela de Medicina; Ferrés, Marcela; 0000-0001-9415-4657; 66180
dc.information.autorucEscuela de Medicina; Le Corre Pérez, Monique Nicole; 0000-0002-9361-4049; 6737
dc.issue.numero9
dc.language.isoen
dc.nota.accesocontenido parcial
dc.pagina.finale382
dc.pagina.inicioe371
dc.revistaThe Lancet Infectious Diseases
dc.rightsacceso restringido
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.subject.ods03 Good health and well-being
dc.subject.odspa03 Salud y bienestar
dc.titleHantavirus in humans: a review of clinical aspects and management
dc.typeartículo
sipa.codpersvinculados66180
sipa.codpersvinculados6737
sipa.trazabilidadORCID;2025-03-03
Files
Collections
Artículos de revistas